To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Substudy A

Inclusion Criteria:

• Male or female participants ≥16 years of age at Visit 1 (Day 1) who participated inC4591001.

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent.

• Participants who have received 2 prior doses of 30 µg BNT162b2 19-42 days apart,with the second dose being at least 175 days before Visit 1 (Day 1).

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behavior or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Prior receipt of any COVID-19 vaccine other than BNT162b2.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID-19.

• Prior receipt of more than 2 doses of BNT162b2 30 µg.

• Participation in other studies involving study intervention within 28 days prior tostudy entry, other than C4591001, and/or within 28 days of confirmed receipt ofBNT162b2 within the study.

Substudy B

Inclusion Criteria:

• Male or female participants 12 to 30 years of age, inclusive, who have received 2prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being atleast at least 4 months (120 days) before Visit 1 (Day 1)

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent.

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behaviour or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Prior receipt of any COVID-19 vaccine other than BNT162b2.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID-19.

• Prior receipt of more than 3 doses of BNT162b2 30 µg.

• Participation in other studies involving study intervention within 28 days prior tostudy entry through and including 28 days after the last dose of study intervention,with the exception of non-Pfizer interventional studies for prevention of COVID-19,which are prohibited throughout study participation.

Substudy C

Inclusion Criteria:

• Male or female participants ≥12 years of age, inclusive, who have received 2 priordoses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least 150days before Visit 301 (Day 1)

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent.

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behaviour or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Prior receipt of any COVID-19 vaccine other than BNT162b2.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID-19.

• Prior receipt of more than 2 doses of BNT162b2 30 µg.

• Participation in other studies involving study intervention within 28 days prior tostudy entry through and including 28 days after the last dose of study intervention,with the exception of non-Pfizer interventional studies for prevention of COVID-19,which are prohibited throughout study participation.

Substudy D

Inclusion Criteria:

• Male or female participants 18 to 55 years of age inclusive

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Cohort 2: Participants who provided a serum sample at Visit 3 in Study C4591001,with Visit 3 occurring within the protocol-specified window.

• Capable of giving signed informed consent

• Cohort 1: Participants who have received 2 prior doses of 30 µg BNT162b2, with thesecond dose being 90 to 240 days before Visit 401 (Day 1) or Cohort 2: Participantswho have received 3 prior doses of 30 µg BNT162b2, with the third dose being 90 to 180 days before Visit 401 (Day 1).

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behavior or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Cohorts 1 and 2: prior receipt of any COVID-19 vaccine other than BNT162b2.

• Cohort 3 only: prior receipt of any COVID-19 vaccine.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID 19.

• Participation in other studies involving study intervention within 28 days prior tostudy entry through and including 28 days after the last dose of study intervention,with the exception of non-Pfizer interventional studies for prevention of COVID-19,which are prohibited throughout study participation.

Substudy E

Inclusion Criteria:

• Groups 1-6: Male or female participants >55 years of age

• Groups 7-9: Male or female participants 18 to 55 years of age

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent.

• Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dosebeing 5 to 12 months (150 to 360 days) before Visit 601 (Day 1).

• Groups 7 to 9 (sentinel participants): Screening troponin levels must be withinnormal range prior to randomization.

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behavior or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Prior receipt of any COVID-19 vaccine other than BNT162b2.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID-19.

• Participation in other studies involving study intervention within 28 days prior tostudy entry through and including 28 days after the last dose of study intervention,with the exception of non-Pfizer interventional studies for prevention of COVID-19,which are prohibited throughout study participation.

Substudy F

Inclusion Criteria:

• Male or female participants ≥60 years of age

• Participants who are willing and able to comply with all scheduled visits,vaccination plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent.

• Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dosebeing ≥4 months before Visit 701 (Day 1).

Exclusion Criteria:

• Other medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behavior or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• History of severe adverse reaction associated with a vaccine and/or severe allergicreaction (eg, anaphylaxis) to any component of the study intervention.

• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAATresult was not available) or microbiological (based on COVID-19 symptoms/signs and apositive SARS-CoV-2 NAAT result) diagnosis of COVID-19.

• Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant or breastfeeding.

• Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids, eg, for cancer or anautoimmune disease, or planned receipt throughout the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60days before study intervention administration, or receipt of any passive antibodytherapy specific to COVID-19, from 90 days before study intervention administration,or planned receipt throughout the study.

• Prior receipt of any COVID-19 vaccine other than BNT162b2.

• Investigator site staff or Pfizer/BioNTech employees directly involved in theconduct of the study, site staff otherwise supervised by the investigator, and theirrespective family members.

• Receipt of medications intended to prevent COVID-19.

• Participation in other studies involving study intervention within 28 days prior tostudy entry through and including 28 days after the last dose of study intervention,with the exception of non-Pfizer interventional studies for prevention of COVID-19,which are prohibited throughout study participation.